Seijiro Minamoto

Suggest Changes
Learn More
BACKGROUND Omalizumab is a humanized monoclonal anti-IgE antibody that was recently approved for the treatment of severe allergic asthma. However, omalizumab is not licensed for allergic asthma in(More)
  • 1